Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Chengdu Olymax In-Licenses China Rights to Australian Strep Vaccine Candidate

publication date: Aug 4, 2016

Chengdu Olymvax Biopharma has in-licensed greater China rights to a novel Group A Streptococcus (GAS) vaccine developed by Australia's Griffith University. Olymvax will manufacture the vaccine for Phase I clinical trials that will be conducted concurrently in China and Australia. The needle-free vaccine is delivered in a single dose through the nose, which facilitates access to lung lining tissue, the location for most strep infections.Olymvax will pay Griffith royalties on sales and also make milestone payments. Specific details of the agreement were not disclosed. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020